The 5 Most Clinically Impactful Papers Published in 2024 and Beyond
DOI:
https://doi.org/10.58931/cibdt.2025.3138Abstract
This past year saw the publication of a number of highly influential papers that have had immediate impacts on how we care for patients with Inflammatory bowel disease (IBD). In this review, I have selected five articles detailing studies published since the beginning of 2024 that have already directly impacted how I manage the care of people living with IBD. These articles are essential reading for all Canadian physicians treating IBD.
References
Singh S, Murad MH, Fumery M, Sedano R, Jairath V, Panaccione R, et al. Comparative efficacy and safety of biologic therapies for moderate-to-severe Crohn’s disease: a systematic review and network meta-analysis. Lancet Gastroenterol Hepatol. 2021;6(12):1002-1014. doi:10.1016/s2468-1253(21)00312-5 DOI: https://doi.org/10.1016/S2468-1253(21)00312-5
Barberio B, Gracie DJ, Black CJ, Ford AC. Efficacy of biological therapies and small molecules in induction and maintenance of remission in luminal Crohn’s disease: systematic review and network meta-analysis. Gut. 2023;72(2):264-274. doi:10.1136/gutjnl-2022-328052 DOI: https://doi.org/10.1136/gutjnl-2022-328052
Ben-Horin S, Novack L, Mao R, Guo J, Zhao Y, Sergienko R, et al. Efficacy of biologic drugs in short-duration versus long-duration inflammatory bowel disease: a systematic review and an individual-patient data meta-analysis of randomized controlled trials. Gastroenterology. 2022;162(2):482-494. doi:10.1053/j.gastro.2021.10.037 DOI: https://doi.org/10.1053/j.gastro.2021.10.037
Targownik LE, Bernstein CN, Benchimol EI, Kaplan GG, Singh H, Tennakoon A, et al. Earlier anti-TNF initiation leads to long-term lower health care utilization in Crohn’s disease but not in ulcerative colitis. Clin Gastroenterol Hepatol. 2022;20(11):2607-2618.e2614. doi:10.1016/j.cgh.2022.02.021 DOI: https://doi.org/10.1016/j.cgh.2022.02.021
Noor NM, Lee JC, Bond S, Dowling F, Brezina B, Patel KV, et al. A biomarker-stratified comparison of top-down versus accelerated step-up treatment strategies for patients with newly diagnosed Crohn’s disease (PROFILE): a multicentre, open-label randomised controlled trial. Lancet Gastroenterol Hepatol. 2024;9(5):415-427. doi:10.1016/s2468-1253(24)00034-7 DOI: https://doi.org/10.1016/S2468-1253(24)00034-7
Yanai H, Goren I, Godny L, Maharshak N, Ron Y, Avni Biron I, et al. Early indolent course of Crohn’s disease in newly diagnosed patients is not rare and possibly predictable. Clin Gastroenterol Hepatol. 2021;19(8):1564-1572.e1565. doi:10.1016/j.cgh.2020.06.069 DOI: https://doi.org/10.1016/j.cgh.2020.06.069
Chanchlani N, Lin S, Bewshea C, Hamilton B, Thomas A, Smith R, et al. Mechanisms and management of loss of response to anti-TNF therapy for patients with Crohn’s disease: 3-year data from the prospective, multicentre PANTS cohort study. Lancet Gastroenterol Hepatol. 2024;9(6):521-538. doi:10.1016/s2468-1253(24)00044-x DOI: https://doi.org/10.1016/S2468-1253(24)00044-X
Yang H, Huang Z, Li M, Zhang H, Fu L, Wang X, et al. Comparative effectiveness of ustekinumab vs. vedolizumab for anti-TNF-naïve or anti-TNF-exposed Crohn’s disease: a multicenter cohort study. eClinicalMedicine. 2023;66. doi:10.1016/j.eclinm.2023.102337 DOI: https://doi.org/10.1016/j.eclinm.2023.102337
Verstockt B, Salas A, Sands BE, Abraham C, Leibovitzh H, Neurath MF, et al. IL-12 and IL-23 pathway inhibition in inflammatory bowel disease. Nat Rev Gastroenterol Hepatol. 2023;20(7):433-446. doi:10.1038/s41575-023-00768-1 DOI: https://doi.org/10.1038/s41575-023-00768-1
D’Haens G, Panaccione R, Baert F, Bossuyt P, Colombel JF, Danese S, et al. Risankizumab as induction therapy for Crohn’s disease: results from the phase 3 ADVANCE and MOTIVATE induction trials. Lancet. 2022;399(10340):2015-2030. doi:10.1016/s0140-6736(22)00467-6 DOI: https://doi.org/10.1016/S0140-6736(22)00467-6
Peyrin-Biroulet L, Chapman JC, Colombel JF, Caprioli F, D’Haens G, Ferrante M, et al. Risankizumab versus ustekinumab for moderate-to-severe Crohn’s disease. N Engl J Med. 2024;391(3):213-223. doi:10.1056/NEJMoa2314585 DOI: https://doi.org/10.1056/NEJMoa2314585
Kalman TD, Everhov ÅH, Nordenvall C, Sachs MC, Halfvarson J, Ekbom A, et al. Decrease in primary but not in secondary abdominal surgery for Crohn’s disease: nationwide cohort study, 1990–2014. Br J Surg. 2020;107(11):1529-1538. doi:10.1002/bjs.11659 DOI: https://doi.org/10.1002/bjs.11659
Frolkis AD, Dykeman J, Negron ME, Debruyn J, Jette N, Fiest KM, et al. Risk of surgery for inflammatory bowel diseases has decreased over time: a systematic review and meta-analysis of population-based studies. Gastroenterology. 2013;145(5):996-1006. doi:10.1053/j.gastro.2013.07.041 DOI: https://doi.org/10.1053/j.gastro.2013.07.041
Nardone OM, Calabrese G, Barberio B, Giglio MC, Castiglione F, Luglio G, et al. Rates of endoscopic recurrence in postoperative Crohn’s disease based on anastomotic techniques: a systematic review and meta-analysis. Inflamm Bowel Dis. 2024;30(10):1877-1887. doi:10.1093/ibd/izad252 DOI: https://doi.org/10.1093/ibd/izad252
Rutgeerts P, Geboes K, Vantrappen G, Beyls J, Kerremans R, Hiele M. Predictability of the postoperative course of Crohn’s disease. Gastroenterology. 1990;99(4):956-963. doi:10.1016/0016-5085(90)90613-6 DOI: https://doi.org/10.1016/0016-5085(90)90613-6
Regueiro M, Kip KE, Baidoo L, Swoger JM, Schraut W. Postoperative therapy with infliximab prevents long-term Crohn’s disease recurrence. Clin Gastroenterol Hepatol. 2014;12(9):1494-1502 e1491. doi:10.1016/j.cgh.2013.12.035 DOI: https://doi.org/10.1016/j.cgh.2013.12.035
Collins M, Sarter H, Gower-Rousseau C, Koriche D, Libier L, Nachury M, et al. Previous exposure to multiple anti-TNF is associated with decreased efficiency in preventing postoperative Crohn’s disease recurrence. J Crohn’s Colitis. 2016;11(3):281-288. doi:10.1093/ecco-jcc/jjw151 DOI: https://doi.org/10.1093/ecco-jcc/jjw151
D’Haens G, Taxonera C, Lopez-Sanroman A, Nos P, Danese S, Armuzzi A, et al. Vedolizumab to prevent postoperative recurrence of Crohn’s disease (REPREVIO): a multicentre, double-blind, randomised, placebo-controlled trial. Lancet Gastroenterol Hepatol. 2025;10(1):26-33. doi:10.1016/S2468-1253(24)00317-0 DOI: https://doi.org/10.1016/S2468-1253(24)00317-0
Tsai L, Nguyen NH, Ma C, Prokop LJ, Sandborn WJ, Singh S. Systematic review and meta-analysis: risk of hospitalization in patients with ulcerative colitis and Crohn’s disease in population-based cohort studies. Dig Dis Sci. 2022;67(6):2451-2461. doi:10.1007/s10620-021-07200-1 DOI: https://doi.org/10.1007/s10620-021-07200-1
Festa S, Scribano ML, Pugliese D, Bezzio C, Principi M, Ribaldone DG, et al. Long-term outcomes of acute severe ulcerative colitis in the rescue therapy era: a multicentre cohort study. United European Gastroenterol J. 2021;9(4):507-516. doi:10.1177/2050640620977405 DOI: https://doi.org/10.1177/2050640620977405
Turner D, Walsh CM, Steinhart AH, Griffiths AM. Response to corticosteroids in severe ulcerative colitis: a systematic review of the literature and a meta-regression. Clin Gastroenterol Hepatol. 2007;5(1):103-110. doi:10.1016/j.cgh.2006.09.033 DOI: https://doi.org/10.1016/j.cgh.2006.09.033
Laharie D, Bourreille A, Branche J, Allez M, Bouhnik Y, Filippi J, et al. Long-term outcome of patients with steroid-refractory acute severe UC treated with ciclosporin or infliximab. Gut. 2018;67(2):237-243. doi:10.1136/gutjnl-2016-313060 DOI: https://doi.org/10.1136/gutjnl-2016-313060
Battat R, Hemperly A, Truong S, Whitmire N, Boland BS, Dulai PS, et al. Baseline clearance of infliximab is associated with requirement for colectomy in patients with acute severe ulcerative colitis. Clin Gastroenterol Hepatol. 2021;19(3):511-518.e516. doi:10.1016/j.cgh.2020.03.072 DOI: https://doi.org/10.1016/j.cgh.2020.03.072
Gibson DJ, Doherty J, McNally M, Campion J, Keegan D, Keogh A, et al. Comparison of medium to long-term outcomes of acute severe ulcerative colitis patients receiving accelerated and standard infliximab induction. Frontline Gastroenterol. 2020;11(6):441-447. doi:10.1136/flgastro-2019-101335 DOI: https://doi.org/10.1136/flgastro-2019-101335
Choy MC, Li Wai Suen CFD, Con D, Boyd K, Pena R, Burrell K, et al. Intensified versus standard dose infliximab induction therapy for steroid-refractory acute severe ulcerative colitis (PREDICT-UC): an open-label, multicentre, randomised controlled trial. Lancet Gastroenterol Hepatol. 2024;9(11):981-996. doi:10.1016/S2468-1253(24)00200-0 DOI: https://doi.org/10.1016/S2468-1253(24)00200-0
Gecse K, Van Oostrom J, Rietdijk S, Frigstad SO, Doherty G, Irving P, et al. DOP056 TDM-based dose-intensification of infliximab is not superior to standard dosing in patients with acute severe ulcerative colitis: results from the TITRATE study. Journal of Crohn’s and Colitis. 2025;19(Supplement_1):i194-i195. doi:10.1093/ecco-jcc/jjae190.0095 DOI: https://doi.org/10.1093/ecco-jcc/jjae190.0095
Berinstein JA, Karl T, Patel A, Dolinger M, Barrett TA, Ahmed W, et al. Effectiveness of upadacitinib for patients with acute severe ulcerative colitis: a multicenter experience. Am J Gastroenterol. 2024. Published online March 27, 2024. doi:10.14309/ajg.0000000000002674 DOI: https://doi.org/10.14309/ajg.0000000000002674
Ban L, Tata LJ, Humes DJ, Fiaschi L, Card T. Decreased fertility rates in 9639 women diagnosed with inflammatory bowel disease: a United Kingdom population-based cohort study. Aliment Pharmacol Ther. 2015;42(7):855-866. doi:10.1111/apt.13354 DOI: https://doi.org/10.1111/apt.13354
Ali MF, He H, Friedel D. Inflammatory bowel disease and pregnancy: fertility, complications and treatment. Ann Gastroenterol. 2020;33(6):579-590. doi:10.20524/aog.2020.0536 DOI: https://doi.org/10.20524/aog.2020.0536
Nguyen GC, Seow CH, Maxwell C, Huang V, Leung Y, Jones J, et al. The Toronto Consensus Statements for the Management of Inflammatory Bowel Disease in Pregnancy. Gastroenterology. 2016;150(3):734-757 e731. doi:10.1053/j.gastro.2015.12.003 DOI: https://doi.org/10.1053/j.gastro.2015.12.003
Mårild K, Söderling J, Stephansson O, Axelrad J, Halfvarson J, Bröms G, et al. Histologic remission in inflammatory bowel disease and female fertility: a nationwide study. Gastroenterology. 2024;166(5):802-814.e818. doi:10.1053/j.gastro.2024.01.018 DOI: https://doi.org/10.1053/j.gastro.2024.01.018
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Canadian IBD Today
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
